Next Article in Journal
B Cell Tolerance in Health and Disease
Previous Article in Journal
IgE and Drug Allergy: Antibody Recognition of ‘Small’ Molecules of Widely Varying Structures and Activities
Previous Article in Special Issue
T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications
Review

Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases

1
Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen 52074, Germany
2
Pharmedartis GmbH, Aachen 52074, Germany
3
Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen 52074, Germany
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Antibodies 2014, 3(1), 92-115; https://doi.org/10.3390/antib3010092
Received: 19 November 2013 / Revised: 23 January 2014 / Accepted: 28 January 2014 / Published: 19 February 2014
(This article belongs to the Special Issue Recombinant Immunotoxins)
Targeted therapies for the treatment of cancer, but also inflammation and autoimmune diseases will reduce major side effects accompanied with conventional treatment modalities. The immunotoxin concept uses bacterial or plant toxins, coupled to antibodies or natural ligands targeting cancer cells. Initially, immunotoxins suffered from drawbacks like nonspecific cytotoxicity. Even the third generation of immunotoxins comprised of truncated antibodies and modified effector molecules experienced clinical set-backs due to immune responses. Long-term treatment of cancer and non-life-threatening chronic inflammatory diseases requires their complete ‘humanization’. This lead to evaluating human cytolytic fusion proteins (hCFPs), based on human apoptosis-inducing proteins. Lacking an endogenous translocation domain dramatically reduces the cell-death inducing capacity of such proteins. Here, we report on optimizing hCFPs, based on the anti-CD64 single chain variable fragment H22(scFv), specifically eliminating CD64+ macrophages and malignant progenitor cells. We replaced the bacterial toxin in H22(scFv)-ETA' with the pro-apoptotic human granzyme B or angiogenin. Translocation was promoted by a sophisticated adapter containing a membrane transfer peptide (MTD) flanked by endosomal and cytosolic cleavable peptides, thus achieving in vitro cytotoxic activity comparable to bacterial immunotoxins. We demonstrate for the first time that optimized hCFPs, based on granzyme B or angiogenin, can compete with classical ETA-based immunotoxins. View Full-Text
Keywords: immunotherapy; immunotoxin; humanization; CD64; granzyme B; angiogenin; endosomal release immunotherapy; immunotoxin; humanization; CD64; granzyme B; angiogenin; endosomal release
Show Figures

Figure 1

MDPI and ACS Style

Berges, N.; Hehmann-Titt, G.; Hristodorov, D.; Melmer, G.; Thepen, T.; Barth, S. Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases. Antibodies 2014, 3, 92-115. https://doi.org/10.3390/antib3010092

AMA Style

Berges N, Hehmann-Titt G, Hristodorov D, Melmer G, Thepen T, Barth S. Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases. Antibodies. 2014; 3(1):92-115. https://doi.org/10.3390/antib3010092

Chicago/Turabian Style

Berges, Nina, Grit Hehmann-Titt, Dmitrij Hristodorov, Georg Melmer, Theo Thepen, and Stefan Barth. 2014. "Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases" Antibodies 3, no. 1: 92-115. https://doi.org/10.3390/antib3010092

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop